Relevant bibliographies by topics / Lung cancer; real-world evidence; patient registry

Contents

  1. Journal articles
  2. Reports

Academic literature on the topic 'Lung cancer; real-world evidence; patient registry'

Author: Grafiati
Published: 7 June 2025
Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lung cancer; real-world evidence; patient registry.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lung cancer; real-world evidence; patient registry"

1

Bílek, Ondřej, Iveta Selingerová, Michal Kysela, et al. "Current real-world evidence on characteristics and treatment patterns of lung cancer in the single cancer center in the Czech Republic – data from Masaryk Memorial Cancer Institute registry in 2018–2022." Klinická onkologie 37, no. 6 (2024): 433–44. https://doi.org/10.48095/ccko2024433.

Full text
Abstract:
<em><strong>Background</strong></em>: Lung cancer (LC) represents the leading cause of cancer-related deaths in the Czech Republic. Over the past decade, there have been notable advancements in LC treatment based on findings from controlled clinical trials (CTs). However, patients enrolled in CTs may not fully represent the diversity of real-world patient populations from routine clinical practice. To address this gap, we designed an observational retrospective study to describe the real-world evidence of LC treatment from a single-center registry.&nbsp;<em><strong>Patients and methods</strong
APA, Harvard, Vancouver, ISO, and other styles
2

Shaw, Clare, Naureen Starling, Adam Reich, et al. "Modification of systemic anti-cancer therapies and weight loss, a population-level real-world evidence study." Therapeutic Advances in Medical Oncology 12 (January 2020): 175883592098280. http://dx.doi.org/10.1177/1758835920982805.

Full text
Abstract:
Background: Involuntary weight loss may occur during systemic anti-cancer therapy (SACT), causing treatment disruption and poorer prognoses. There remain gaps in clinical awareness as to which patients may benefit from nutritional interventions that aim to prevent unintended weight loss during SACT. We utilised England’s population-level cancer registry data, conducting a pan-cancer assessment of patient weight loss during SACT. We aimed to identify cancers with weight loss-associated treatment modifications, potential beneficiaries of nutritional intervention. Methods: This cross-sectional st
APA, Harvard, Vancouver, ISO, and other styles
3

Law, Jennifer H., Christopher Pettengell, Lisa W. Le, et al. "Generating real-world evidence: Using automated data extraction to replace manual chart review." Journal of Clinical Oncology 37, no. 15_suppl (2019): e18096-e18096. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e18096.

Full text
Abstract:
e18096 Background: Real world evidence is a valuable resource to help guide clinical care beyond evidence generated from clinical trials, for example safety and effectiveness of novel treatments in special populations. Administrative databases often lack sufficient clinical detail to address gaps in the improvement of patient management and quality of care. Detailed clinical data collection and curation are resource intensive, limiting the ability to generate and maintain large informative cancer databases. Darwen, novel technology developed by Pentavere, enables the automation of data abstrac
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Xiaoliang, Blythe J. Adamson, Katherine Tan, Shrujal Baxi, Andrew Briggs, and Scott D. Ramsay. "OP520 Evaluating Long-Term Survival From Clinical Trials: Does Real-World Evidence Change the Paradigm?" International Journal of Technology Assessment in Health Care 36, S1 (2020): 12. http://dx.doi.org/10.1017/s026646232000118x.

Full text
Abstract:
IntroductionBoth patient composition and medical care received in clinical trials may not be representative of clinical practice, yet health technology assessments (HTAs) commonly use extrapolation results from trials to estimate incremental benefit. Due to data limitations, external validation of trial extrapolations are uncommon. With the goal of better estimating the benefit of new therapies in practice, we compared long-term survival estimated from real-world patients who received therapy similar to the comparator arm of the OAK trial, a phase III study of patients with advanced non-small
APA, Harvard, Vancouver, ISO, and other styles
5

Park, Cheol-Kyu, Nakyung Jeon, Hwa-Kyung Park, et al. "A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer." Cancers 15, no. 5 (2023): 1606. http://dx.doi.org/10.3390/cancers15051606.

Full text
Abstract:
This study aimed to add real-world evidence to the literature regarding the effectiveness and safety of durvalumab consolidation (DC) after concurrent chemoradiotherapy (CCRT) in the treatment of unresectable stage III non-small cell lung cancer (NSCLC). Using a hospital-based NSCLC patient registry and propensity score matching in a 2:1 ratio, we conducted a retrospective cohort study of patients with unresectable stage III NSCLC who completed CCRT with and without DC. The co-primary endpoints were 2-year progression-free survival and overall survival. For the safety evaluation, we evaluated
APA, Harvard, Vancouver, ISO, and other styles
6

Anttalainen, Anna, Paavo Pietarinen, Samuli Tuominen, Riikka Mattila, Aino Mutka, and Aija Knuuttila. "Real-World Evidence Study of Patients with KRAS-Mutated NSCLC in Finland." Current Oncology 31, no. 5 (2024): 2700–2712. http://dx.doi.org/10.3390/curroncol31050205.

Full text
Abstract:
While KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), KRAS-mutant tumors have long been considered difficult to treat and thus, an unmet need still remains. Partly due to the lack of targeted treatments, comprehensive real-world description of NSCLC patients with KRAS mutation is still largely missing in Finland. In this study, all adult patients diagnosed with locally advanced and unresectable or metastatic NSCLC from 1 January 2018 to 31 August 2020 at the Hospital District of Helsinki and Uusimaa were first identified in this retrospective registry-based
APA, Harvard, Vancouver, ISO, and other styles
7

Horvat, Pia, Christen M. Gray, Alexandrina Lambova, et al. "Comparing Findings From a Friends of Cancer Research Exploratory Analysis of Real-World End Points With the Cancer Analysis System in England." JCO Clinical Cancer Informatics, no. 5 (December 2021): 1155–68. http://dx.doi.org/10.1200/cci.21.00013.

Full text
Abstract:
PURPOSE This study compared real-world end points extracted from the Cancer Analysis System (CAS), a national cancer registry with linkage to national mortality and other health care databases in England, with those from diverse US oncology data sources, including electronic health care records, insurance claims, unstructured medical charts, or a combination, that participated in the Friends of Cancer Research Real-World Evidence Pilot Project 1.0. Consistency between data sets and between real-world overall survival (rwOS) was assessed in patients with immunotherapy-treated advanced non–small
APA, Harvard, Vancouver, ISO, and other styles
8

Noda-Narita, Shoko, Asuka Kawachi, Ayako Okuyama, et al. "First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data." PLOS ONE 16, no. 9 (2021): e0257489. http://dx.doi.org/10.1371/journal.pone.0257489.

Full text
Abstract:
Aging of the population has led to an increase in the prevalence of cancer among older adults. In Japan, single agent chemotherapy was recommended for advanced non-small cell lung cancer (NSCLC) for those, who were aged ≥75 years, while the Western guidelines did not recommend a specific regimen. In clinical practice, physicians are required to decide the treatment based on a lack of enough evidence. This study aimed to examine the prescribing patterns of first-line chemotherapy according to age in the real-world practice. Data from the survey database of Diagnostic Procedure Combination and h
APA, Harvard, Vancouver, ISO, and other styles
9

Rivera, Donna R. R., Laura Lasiter, Jennifer Christian, et al. "Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration." Journal of Clinical Oncology 38, no. 15_suppl (2020): e19270-e19270. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19270.

Full text
Abstract:
e19270 Background: Friends of Cancer Research convened 9 data partners to identify data elements and common definitions for real world (rw) endpoints to evaluate populations typically excluded from clinical trials. Here we report on rwOS by frontline treatment and comorbidities. Methods: A retrospective observational analysis of patients with aNSCLC initiating frontline platinum doublet chemotherapy (chemo) or PD-(L)1-based immuno-oncologic (IO) therapy (monotherapy or chemo combination) between 1 Jan 2011 to 31 Mar 2018 was conducted using administrative claims, EHR, and cancer registry RWD.
APA, Harvard, Vancouver, ISO, and other styles
10

La, Jennifer, David Cheng, Nhan Do, Mary T. Brophy, Nathanael Fillmore, and David P. Tuck. "Real-world usage and outcomes for patients treated with immune checkpoint inhibitors across multiple treatment indications in the Veterans Affairs system." Journal of Clinical Oncology 38, no. 15_suppl (2020): e15063-e15063. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15063.

Full text
Abstract:
e15063 Background: Increasingly broad patient groups are being treated with immune checkpoint inhibitors (ICIs) in clinical practice, but few studies have assessed their usage and outcomes in large, comprehensive real-world cohorts. In this study, we identified patients who received ICI therapy through April 2019 in the Veterans Affairs (VA) system. We described patient characteristics and assessed survival outcomes for patients across multiple treatment indications based on the cancer type and line of therapy. Methods: We conducted a retrospective analysis using electronic health record data
APA, Harvard, Vancouver, ISO, and other styles
More sources

Reports on the topic "Lung cancer; real-world evidence; patient registry"

1

Tipton, Kelley, Brian F. Leas, Emilia Flores, et al. Impact of Healthcare Algorithms on Racial and Ethnic Disparities in Health and Healthcare. Agency for Healthcare Research and Quality (AHRQ), 2023. http://dx.doi.org/10.23970/ahrqepccer268.

Full text
Abstract:
Objectives. To examine the evidence on whether and how healthcare algorithms (including algorithm-informed decision tools) exacerbate, perpetuate, or reduce racial and ethnic disparities in access to healthcare, quality of care, and health outcomes, and examine strategies that mitigate racial and ethnic bias in the development and use of algorithms. Data sources. We searched published and grey literature for relevant studies published between January 2011 and February 2023. Based on expert guidance, we determined that earlier articles are unlikely to reflect current algorithms. We also hand-se
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Lung cancer; real-world evidence; patient registry' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography